title: Biomedical Innovation: Lessons From the Past and Perspectives for the Future.
abstract: Back around the turn of the millennium, the future of the pharmaceutical industry was bright. Amazing technologies were converging to enable a top-to-bottom reengineering of drug research and development (R&D). The "omics," combinatorial chemistry, high-throughput screening, robotic automation, and systems biology, promised to bring order and method to drug research's bewildering complexity. Pharmaceutical executives-many of whom were ill at ease with their scientists' freewheeling ways-were excited. Gushing with an enthusiasm that was typical of the times, a former industry Chief Executive Officer spoke glowingly of the launch of "two to three new blockbusters… each year" driving a quadrupling of revenues.
authors.affiliation: FasterCures (a center of the Milken Institute), Washington, D.C., USA.
authors.forename: B H
authors.initials: BH
authors.lastname: Munos
mesh_terms: D001331:Automation; D035843:Biomedical Research / Q000191:economics / Q000639:trends*; D020811:Biomedical Technology / Q000191:economics / Q000639:trends*; D020650:Combinatorial Chemistry Techniques; D004059:Diffusion of Innovation; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D057166:High-Throughput Screening Assays / Q000639:trends; D006801:Humans; D012371:Robotics / Q000639:trends; D049490:Systems Biology / Q000639:trends